UAB Recessive PKD Research and Translational Core Center (UAB RPKDCC)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00575705
First received: December 13, 2007
Last updated: March 15, 2011
Last verified: March 2011

December 13, 2007
March 15, 2011
November 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00575705 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
UAB Recessive PKD Research and Translational Core Center
The ARPKD Clinical and Genetic Resource (UAB Recessive PKD Research and Translational Core Center)

The University of Alabama at Birmingham Recessive Polycystic Kidney Disease Core Center (UAB RPKDCC) has established a NIDDK-funded, interdisciplinary center of excellence in PKD-related research, with specific emphasis on recessive PKD. Among the five Cores, the UAB RPKDCC includes the ARPKD Clinical and Genetic Resource, a Core resource designed to develop a unique set of clinical, genetic, and educational resources for ARPKD. The Core has three primary objectives:

  1. To extend the observational study of ARPKD initiated by the North American ARPKD Database.
  2. To provide a mechanism for genetic evaluation of patients with both classic ARPKD and unusual phenotypes of recessive PKD.
  3. To develop educational tools for physicians and patients regarding the natural history, cause, development and effects of the disease, genetic testing, and clinical trials applicable to ARPKD.

The Study protocol and the Informed Consent for the Clinical Database will be posted on the website (http://www.arpkdstudies.uab.edu/) for review by potential participants and follow-up discussions with the PI and/or Research Nurse Coordinator. In addition, materials in paper format can be sent to interested potential participants upon request.

Two key elements will be required for patient enrollment: 1) certification that informed consent has been obtained, and 2) certification that permission for release of selected health information has also been obtained, including the date of signature. Once receipt of these items is confirmed, the following actions will proceed:

  1. the participant will be assigned a unique identifier in the database and a clinician-specific web field will be opened for that identifier.
  2. the participant/parents will confirm the name of their clinician to the database and notify their physician and/or genetic counselor (clinicians) of their intent to participate in this study.
  3. the clinician will access the Physician Link on the website, type in the patient name and the referring center, and if matched to the patient's report, will receive the unique identifier for that patient. Once this is done, the name of the patient will be deleted from the online database and only the unique identifier will be used. Each clinician permitted to access this website will be tracked with a login procedure that includes a process to verify who is entering the system.
  4. This unique identifier will allow the clinician to open the clinical database entry form and provide the information requested in each field. No names or initials will be collected in this data form, but gender and date of birth (which will be converted to age and only the month and year will be kept on file) will be requested.
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:

Blood-derived DNA and lymphocytes for EBV-immortalized cell lines.

Non-Probability Sample

In view of the genetics and demographics of ARPKD in North America, we estimate that 50% of the subjects will be female; that 90% of the subjects will be Caucasian and the remainder will belong to the following racial/ethnic categories: 5% African-Americans; 3% Hispanics; 1% Asians; and 1% or less will be other categories.

Autosomal Recessive Polycystic Kidney Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
200
November 2010
Not Provided

Inclusion Criteria:

  • Histopathology compatible with ARPKD based on renal biopsy or necropsy; or
  • Sonographic evidence of diffusely enlarged, echogenic kidneys and at least one additional criteria:

    1. patho-anatomical diagnosis in an affected sibling, or
    2. absence of renal cysts in the ultrasound examination of both parents (studies would have been obtained as part of the evaluation of the affected child; parents must be > 30 yo), or
    3. hepatic fibrosis based on either clinical or histopathologic evidence, or
    4. parental consanguinity

Exclusion Criteria:

  • ADPKD
  • Urinary tract malformations
  • Major congenital anomalies of other systems
Both
up to 35 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00575705
P30 DK074038, P30-DK074038
No
Lisa M. Guay-Woodford, University of Alabama at Birmingham
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not Provided
Principal Investigator: Lisa M. Guay-Woodford, MD University of Alabama at Birmingham
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP